Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program [Yahoo! Finance]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Yahoo! Finance
developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus. "We believe there is an opportunity to develop an improved shingles vaccine with a significantly better tolerability profile compared to the market-leading shingles vaccine. One of the unique advantages of our vaccine candidate is CpG 1018 adjuvant's established safety and tolerability profile, combined with its ability to induce strong CD4+ T-cell responses, which are thought to be critical in preventing the reactivation of the herpes zoster virus," said Rob Janssen , M.D., Chief Medical Officer of Dynavax. The Phase 1/2 randomized, active-controlled, dose escalation, multicenter trial is expected to enroll
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- Dynavax Technologies Co. (NASDAQ: DVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- Dynavax doses first subject in Phase I/II shingles vaccine trial [Yahoo! Finance]Yahoo! Finance
- Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine ProgramPR Newswire
- TwoStep Therapeutics Launches with Funding to Advance Broadly Applicable Targeting Platform for Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Dynavax to Present at Upcoming Investor ConferencesPR Newswire
DVAX
Earnings
- 5/8/24 - Miss
DVAX
Sec Filings
- 6/3/24 - Form 4
- 5/28/24 - Form 4
- 5/28/24 - Form 4
- DVAX's page on the SEC website